Management of Metformin in Patients with Renal Impairment

Introduction to Metformin Adjustment

For a patient with an estimated glomerular filtration rate (eGFR) of 39 ml/min/1.73 m², the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend reducing the metformin dose to 250 mg twice daily (halve the dose) to minimize the risk of adverse effects, as metformin is still appropriate for patients with an eGFR ≥30 ml/min/1.73 m² 1
The KDIGO guidelines specifically recommend halving the metformin dose when eGFR is between 30-44 ml/min/1.73 m², which is the case for this patient 1, 2

Metformin is still appropriate for patients with moderate renal impairment, as the eGFR is ≥30 ml/min/1.73 m², but the current dosage requires adjustment to reduce the risk of adverse effects 1, 2
Reducing the metformin dose from 500 mg twice daily to 250 mg twice daily maintains the medication's benefits while reducing the risk of adverse effects, according to the KDIGO guidelines 1

The KDIGO guidelines recommend monitoring kidney function every 3-6 months for patients with moderate renal impairment, which is more frequent than the annual monitoring recommended for patients with normal kidney function 1
Monitoring for vitamin B12 deficiency is especially important if the patient has been on metformin for more than 4 years, as recommended by the KDIGO guidelines 1, 3

If glycemic control is not achieved with the reduced metformin dose, consider adding a sodium-glucose cotransporter 2 (SGLT2) inhibitor as the first choice add-on therapy, if eGFR ≥30 ml/min/1.73 m², as recommended by the KDIGO guidelines 1, 2
A glucagon-like peptide-1 (GLP-1) receptor agonist is the preferred second add-on therapy if additional therapy is needed, according to the KDIGO guidelines 1, 2

Sulfonylureas should not be used as an alternative to metformin in patients with renal impairment, as they carry a higher hypoglycemia risk, according to the American Diabetes Association 4